📰 Luigi Manenti News
Luigi Manenti News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Luigi Manenti. Real-time updates on events, politics, business and more.
May 29, 2024
Lixudebart (ALE.F02) is a first-in-class monoclonal antibody in clinical development for multi-organ fibrosis Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing
October 5, 2023
BASEL, Switzerland--(BUSINESS WIRE)--#CLDN1--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong a...
August 29, 2023
BASEL, Switzerland, August 29, 2023--Late-Breaking Oral Presentation on ALE.F02 as Potential Treatment for Pulmonary Fibrosis
August 25, 2023
Alentis Therapeutics has received fast track designation from the FDA for ALE.C04 to treat patients with head and neck squamous cell carcinoma.
August 25, 2023
The FDA has granted fast track designation to ALE.C04 for use as a potential therapeutic option in patients with recurrent or metastatic, Claudin-1–positive head and neck squamous cell carcinomas.
April 26, 2023
The trial confirms ALE.F02's good safety profile, exposure and target biological activity Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing breakthrough treatments